MedTrace Logo

Training Interventions and Genetics of Exercise Response (TIGER)

NCT01127919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3773

Last updated 2017-11-13

No results posted yet for this study

Summary

Obesity established in adolescence strongly predicts obesity for the remainder of adult life, and the consequences are potentially devastating, characterized by a lifelong burden of co-morbid conditions and depression. This study will provide an exposure to physical activity that is designed to teach and empower sedentary college age individuals to become physically active. The investigators will evaluate whether such exposure can result in lasting changes in exercise behavior and body composition. The study will also provide a better understanding of the genetic factors that influence persistence in an exercise program and that influence whole body response to exercise training. Altering the course of obesity in adolescence has the potential to reduce the adult prevalence of obesity and consequently attenuate the public health burden of overweight and obesity in the investigators population.

Conditions

  • Exercise Response

Interventions

BEHAVIORAL

Aerobic Exercise Training

40 minutes, 3 times a week for 35 weeks.

OTHER

Cognitive Component

Provide general information about health and fitness

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Molly S. Bray

    lead OTHER

Principal Investigators

  • Molly Bray, PhD · University of Alabama at Birmingham

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2016-05-31
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127919 on ClinicalTrials.gov